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Objective: Bronchodilator responsiveness (BDR) is prevalent in COPD, but its clinical
implications remain unclear. We explored the significance of BDR, defined by post-bronch-
odilator change in FEV1 (BDRFEV1) as a measure reflecting the change in flow and in FVC
(BDRFVC) reflecting the change in volume.
Methods:We analyzed 2974 participants from a multicenter observational study designed to
identify varying COPD phenotypes (SPIROMICS). We evaluated the association of BDR
with baseline clinical characteristics, rate of prospective exacerbations and mortality using
negative binomial regression and Cox proportional hazards models.
Results: A majority of COPD participants exhibited BDR (52.7%). BDRFEV1 occurred more
often in earlier stages of COPD, while BDRFVC occurred more frequently in more advanced
disease. When defined by increases in either FEV1 or FVC, BDR was associated with a self-
reported history of asthma, but not with blood eosinophil counts. BDRFVC was more
prevalent in subjects with greater emphysema and small airway disease on CT. In a
univariate analysis, BDRFVC was associated with increased exacerbations and mortality,
although no significance was found in a model adjusted for post-bronchodilator FEV1.
Conclusion: With advanced airflow obstruction in COPD, BDRFVC is more prevalent in
comparison to BDRFEV1 and correlates with the extent of emphysema and degree of small
airway disease. Since these associations appear to be related to the impairment of FEV1, BDRFVC
itself does not define a distinct phenotype nor can it be more predictive of outcomes, but it can
offer additional insights into the pathophysiologic mechanism in advanced COPD.
Clinical trials registration: ClinicalTrials.gov: NCT01969344T4.
Keywords: bronchodilator responsiveness, inspiratory capacity, FVC, FEV1, SPIROMICS
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limita-
tion that persists after bronchodilator (BD) administration and is defined by the
ratio of forced expiratory volume in one second (FEV1) to forced vital capacity
(FVC) (FEV1/FVC) <0.70.
1 Widely accepted guidelines define bronchodilator
responsiveness (BDR) by the increase in FEV1 or FVC of ≥200 mL and ≥12%
relative to pre-BD values.2,3 BDR is common in COPD patients,4,5 but whether it
defines a unique phenotype is incompletely understood. In contrast to BDRFEV1,
which represents a flow-based, time-limited response to bronchodilators, BDRFVC
evaluates the volumetric response and, together with other spirometry-measured
capacities (slow vital capacity [SVC] and inspiratory capacity [IC]), evaluates a BD
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effect that is neither flow-dependent nor time-limited.6
Studies of the response patterns to BD administration in
COPD suggest that reduction in hyperinflation and air
trapping, as reflected by increases in lung volumes, leads
to improvement in symptoms.6,7 Nevertheless, with con-
flicting data about the clinical relevance of BDRFVC in
the assessment of COPD8–11 and the lack of recommenda-
tions about the interpretability of BDR assessed by FVC
and FEV1,
12 a clear understanding of the clinical relevance
of BDR in COPD has been largely missing.
Using data from a large cohort of longitudinally followed
individuals, we evaluated the clinical significance of BDR in
COPD and its relationship to the frequency of COPD exacer-
bations, which are associated with increased morbidity and
mortality.13,14We compared flow- and volume-based respon-
siveness to BD administration and analyzed distinct clinical
implications of FEV1BDR and FVCBDR and their association
with various outcomes.
Methods
Study Design and Participants
Subpopulations and Intermediate Outcome Measures in
COPD (SPIROMICS) is a multi-center observational
study designed to identify different COPD phenotypes.
SPIROMICS enrolled 2,974 participants, ages 40–80 years
into four strata (non-smokers; current and former smokers
without airflow obstruction; and current and former smokers
with either mild/moderate COPD, or severe/very severe
COPD).15 Of these, 1,831 participants had COPD based on
GOLD criteria.12 Subjects with a current diagnosis of asthma
or pulmonary comorbidities not related to COPD were
excluded from participation in the study, although those with
a prior history of asthma that was no longer active were
eligible. Participants completed a baseline examination that
comprised a detailed medical history; blood and sputum bio-
marker analysis; assessment of dyspnea by modified Medical
Research Council (mMRC) scale, of symptoms by COPD
assessment test (CAT), and of health status by St. George’s
Respiratory Questionnaire (SGRQ); spirometry before and
after inhaled BD; and high resolution chest CT scan (HRCT).
Enrolled subjects were classified using GOLD guidelines.12,16
Spirometry
Spirometry was performed using a centrally supplied pneumo-
tachograph following current ATS/ERS recommendations and
using reference values calculated from the Hankinson
equation.3 COPD was defined by a post-BD FEV1/
FVC<0.70. Prior to the testing, participants were asked to
withhold bronchodilators for at least a period equal to twice
the usual dosing frequency. BDRwas tested 30mins after four
inhalations each of albuterol sulfateHFA (90µg/actuation) and
ipratropium bromide HFA (17 µg/actuation).We defined BDR
as an increase in FEV1, FVC, or IC of ≥12% and ≥200 mL.
2
Chest CT Acquisition and Analysis
All SPIROMICS participants underwent HRCTon 64- or 128-
slice helical scanners. Images were obtained at suspended full
inhalation and on exhalation and data were analyzed by
Apollo software (VIDA Diagnostics, Coralville, IA).17
Emphysema scores were derived using percentages of low
attenuation area below and including −950 Hounsfield units
(HU). Parametric response mapping (PRM), a dynamic image
registration technique that links inspiratory and expiratory
features of CT lung scans, was used to assess functional
small airway disease (fSAD) and emphysema.18 PRM was
performed on all CT data automatically using Lung Density
Analysis (LDA™) software application (Imbio, LLC,
Minneapolis, MN). The adopted nomenclature for these mea-
sures for normal lung parenchyma and fSAD is PRMNormal
and PRMfSAD, respectively.
Statistical Analysis
Demographic and clinical characteristics were tabulated,
using mean and standard deviation for continuous variables,
and frequency and percentages for categorical variables. We
compared the clinical differences in clinical characteristics
between BD responders and BD nonresponders using a two-
sample t-test (or Wilcoxon rank sum test, if normality was
not met) for continuous variables and a Chi-square test for
categorical variables. PRMfSAD scores between BD respon-
ders and nonresponders were compared by Wilcoxon rank
sum test. To assess BDR repeatability measured by FEV1,
FVC, and IC, we calculated percentages of positive, nega-
tive, and total agreement, as well as Cohen’s kappa.
We investigated if BDRFVC was associated with
exacerbations using univariate and multivariate negative
binomial models and tested associations of BDRFVC with
3-year survival by univariate and multivariate Cox propor-
tional hazards models and Kaplan–Meier survival func-
tions. For all multivariate modeling, stepwise model
selections were performed to obtain the final parsimonious
model. All tests for significance were two-tailed, using
P-value less than 0.05 as the threshold for significance.
All statistical analyses were conducted using SAS version
9.4 (SAS Institute Inc. 2013).
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Ethics Statement
All investigations were conducted according to the princi-
ples of the Declaration of Helsinki. Protocols were
reviewed and approved by institutional review boards in
each participating site (detailed list of all approving ethics
committees provided in the Supplemental data). All parti-
cipants understood the purpose of the study, and all gave
written informed consent before any procedures.
Results
Demographic Data
Of 2,974 participants, 202 (6.8%) were healthy never-smo-
kers, 941 (31.6%) were current or former smokers without
airflow obstruction, and 1,831 (61.6%) had COPD with one-
third of those having severe or very severe disease defined by
GOLD spirometric staging (Table 1). Mean smoking history
among ever-smokerswas 46 pack-years, and current smokers
comprised 37% of the overall population.
Repeatability of BDR Measured by FEV1,
FVC, and IC
To assess BDR repeatability of flow-based versus
volume-based measurements, we analyzed results of a
published substudy of 98 participants who replicated
their entire baseline evaluation (including spirometry)
2–6 weeks after their initial visit.19 BDRFVC had great-
est repeatability (76.5%, k=0.53), in comparison to
BDRFEV1 (72.4%, k=0.43) or BDRIC (64.2%, k=0.27),
Supplemental Table 1.
BDR in SPIROMICS Cohort
BDR was observed across all participant groups
(Figure 1) and was similar for flow-based (FEV1,
29.0%) and volume-based metrics, including FVC
(26.3%) and SVC (26.5%) or IC (32.1%). Among parti-
cipants without COPD, 7.1% of never-smokers and
13.7% of ever-smokers without obstruction demonstrated
Table 1 Demographic Data in SPIROMICS Cohort
Parameter SPIROMICS
Cohort
(N=2974)
Healthy
Controls
(N=202)
Former or
Current
Smokers
without COPD
(N=941)
Mild/
Moderate
COPD
(N=1207)
Severe/Very
Severe
COPD
(N=624)
COPD
Total
(N=1831)
Age (mean, SD) 63.01 (9.20) 56.5 (10.2) 60.3 (9.7) 65.6 (8.2) 64.3 (7.8) 65.1 (8.1)
Sex (male N, %) 1577 (53.0%) 79 (39.1%) 448 (47.6%) 701 (58.1%) 349 (55.9%) 1050 (57.4%)
Race
White (N, % within the column) 2263 (76.1%) 140 (69.3%) 638 (67.8%) 995 (82.4%) 490 (78.5%) 1485 (81.1%)
Black 576 (19.4%) 46 (22.8%) 250 (26.6%) 169 (14.0%) 111 (17.8%) 280 (15.3%)
Asian 33 (1.1%) 4 (2.0%) 7 (0.7%) 15 (1.3%) 7 (1.1%) 22 (1.2%)
Others 102 (3.4%) 12 (5.9%) 46 (4.9%) 28 (2.3%) 16 (2.6%) 44 (2.4%)
Current smokers (%) 1093 (37.3%) N/A 475 (51.0%) 460 (38.8%) 158 (25.7%) 618 (34.3%)
Cigarette Exposure - pY (ever smokers) (Mean, SD) 45.98 (28.76) N/A 42.73 (24.28) 52.95 (29.57) 52.23 (23.07) 52.71 (27.52)
BMI (Mean, SD) 27.94 (5.27) 28.5 (5.0) 29.0 (5.1) 27.9 (5.2) 26.4 (5.4) 27.4 (5.3)
CBC eosinophil CNTat baseline (x10^9/L) [Mean, (SD)] 0.20 (0.17) 0.15 (0.13) 0.19 (0.15) 0.21 (0.19) 0.21 (0.18) 0.21 (0.19)
CBC eosinophil PCT at baseline [Mean, (SD)] 2.88 (2.08) 2.64 (2.17) 2.84 (2.12) 2.94 (1.93) 2.88 (2.26) 2.92 (2.04)
Chronic bronchitis at baseline (N, %) 596 (21.2%) N/A 128 (14.1%) 251 (22.4%) 216 (37.0%) 467 (27.4%)
History of childhood asthma at baseline (N, %) 245 (8.2%) 4 (2.0%) 64 (6.8%) 115 (9.5%) 62 (9.9%) 177 (9.7%)
Reported history of asthma at baseline (N, %) 573 (19.3%) 10 (5.0%) 148 (15.7%) 264 (21.9%) 151 (24.2%) 415 (22.7%)
Post-BD FEV1 percentage (mean, SD) 74.99 (26.75) 101.8 (11.6%) 96.8 (13.6) 74.0 (15.7) 35.4 (9.9) 60.9 (23.0)
SGRQ (mean, SD) 31.97 (20.99) 9.00 (9.99) 24.81 (19.34) 32.56 (19.07) 48.25 (16.91) 38.01 (19.81)
Use of inhaled bronchodilators (N, %) 1441 (49.0%) N/A 223 (24.0%) 662 (55.4%) 547 (88.8%) 1209 (66.8%)
Use of inhaled steroids (N, %) 973 (33.1%) N/A 111 (11.9%) 432 (36.1%) 425 (68.9%) 857 (47.3%)
Oral corticosteroid use at baseline (N, %) 71 (2.4%) N/A 4 (0.4%) 16 (1.3%) 51 (8.3%) 67 (3.7%)
Cardiovascular condition at baseline (N, %) 1849 (63.0%) 93 (47.0%) 552 (59.3%) 811 (67.9%) 393 (64.3%) 1204 (66.7%)
Congestive heart failure (N, %) 71 (2.4%) 1 (0.5%) 14 (1.5%) 35 (2.9%) 21 (3.4%) 56 (3.1%)
Diabetes (N, %) 392 (13.3%) 19 (9.6%) 123 (13.2%) 178 (14.9%) 72 (11.8%) 250 (13.8%)
GERD (N, %) 865 (29.4%) 36 (18.2%) 264 (28.2%) 393 (32.8%) 172 (28.2%) 565 (31.2%)
Total exacerbations within 12 months at baseline
(mean, SD)
0.42 (0.92) 0.04 (0.20) 0.22 (0.67) 0.39 (0.88) 0.89 (1.23) 0.56 (1.04)
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BDR defined by either FEV1 or FVC. Among those with
BDR, a response was detected more often by BDRFEV1
than by BDRFVC (7.1% vs 2% never smokers; 13% vs
4.5% ever-smokers without obstruction). Comparing
BDR for FVC to BDR for SVC and IC, a lower preva-
lence of BDRFVC was evident in both healthy never-
smokers (BDRFVC 2% vs BDRSVC 5.0% and BDRIC
13.4%) and ever-smokers without obstruction (BDRFVC
4.5% vs BDRSVC 11.6% and BDRIC 22.5%), suggesting
greater ability of BDRFVC parameter to discriminate
between healthy and diseased airways.
Over half of the subjects with COPD displayed FEV1-
or FVC-defined BDR (52.7%) with similar overall fre-
quencies of BDRFEV1 (39.7%) and BDRFVC (40.2%). In
contrast to other groups, COPD subjects showed a greater
prevalence of BDRFVC than BDRIC or BDRSVC (39.1%
and 36.7%, respectively). Accepting categorization of sub-
jects as BD responsive if any of the these four metrics
indicated BDR, we found 67.1% of the participants with
COPD to be BD responders.
BDR Relates to a Reported History of
Asthma but Not to Blood Eosinophil
Counts
Although individuals with currently active non-COPD
obstructive lung disease were not included in
SPIROMICS cohort, participants with COPD had a self-
reported previous history of asthma more frequently than
healthy nonsmokers or former/current smokers (Table 1).
A self-reported history of asthma was significantly more
common in participants who were FEV1- or FVC-BD
responders (Table 2). Neither BDRFVC nor BDRFEV1 was
associated with blood eosinophil counts (BEC), relative to
nonresponders (Table 2).
Volume Responsiveness Increases as
COPD Progresses
Mild COPD (spirometric GOLD grade 1) was character-
ized by greater BDRFEV1 than BDRFVC (35.6% vs 19.2%),
a difference that was less marked in GOLD grades 2 and 3
(Figure 2A). In very severe COPD (spirometric GOLD
Figure 1 Overall BDR defined by different spirometric measures in the SPIROMICS cohort.
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grade 4), BDRFEV1 was infrequent (11.3%). By contrast,
BDRFVC prevalence increased with advanced obstruction
and was observed most frequently (54.3%) in spirometric
GOLD grade 4.
To investigate whether the observed low frequency of
BDRFEV1 in very severe disease was simply a consequence
of low (<30% predicted) baseline FEV1, we performed sen-
sitivity analyses of BDRFEV1 and BDRFVC by dividing
Table 2 Baseline Clinical Characteristics of FVC-BD Responders and FVC-BD Nonresponders
Parameter FEV1-BD
Responders
(n=724)
FEV1-BD
Nonresponders
(n=1102)
P-Value FVC-BD
Responders
(n=734)
FVC-BD
Nonresponders
(n=1092)
P-Value
Age (mean,SD) 64.36 (7.99) 65.63 (8.06) 0.001* 65.0 (7.9) 65.2 (8.2) 0.59
Sex (male N, %) 439 (60.6%) 610 (55.4%) 0.03* 407 (55.5%) 642 (58.8%) 0.16
Current smokers (%) 271 (37.9%) 346 (32.0%) 0.01* 256 (35.4%) 361 (33.7%) 0.46
Cigarette Exposure - pY (ever smokers) (mean, SD) 53.37 (26.98) 52.25 (27.88) 0.40 53.6 (24.5) 52.1 (29.4) 0.25
BMI (mean,SD) 27.65 (5.44) 27.15 (5.23) 0.05 27.4 (5.3) 27.3 (5.4) 0.76
Post-BD FEV1 percentage (mean, SD) 62.08 (18.53) 60.08 (25.53) 0.07 53.1 (19.7) 66.1 (23.6) <0.0001*
History of childhood asthma (N, %) 82 (11.3%) 94 (8.5%) 0.048* 83 (11.3%) 93 (8.5%) 0.048*
Reported history of asthma (N, %) 191 (26.4%) 222 (20.2%) 0.002* 188 (26.6%) 225 (20.6%) 0.012*
SGRQ (mean, SD) 37.74 (19.09) 38.16 (20.31) 0.66 41.4 (19.3) 35.7 (19.9) <0.0001*
CBC eosinophil count (×109/L) (mean, SD) 0.21 (0.23) 0.21 (0.15) 0.49 0.21 (0.16) 0.21 (0.21) 0.56
CBC eosinophil percent (mean, SD) 2.97 (2.10) 2.88 (2.00) 0.36 2.82 (2.02) 2.95 (2.06) 0.39
Use of inhaled bronchodilators (N, %) 492 (68.6%) 713 (65.5%) 0.17 545 (75.3%) 660 (61.0%) <0.0001*
Use of inhaled steroids (N, %) 345 (48.0%) 508 (46.7%) 0.58 384 (52.8%) 469 (43.4%) <0.0001*
Emph % (log-transformed) 1.70 (1.25) 1.81(1.34) 0.03* 1.98 (1.28) 1.62(1.31) <0.0001*
PRM fsad 27.72 (13.43) 26.67 (14.45) 0.07 31.38 (13.36) 24.21 (13.78) <0.0001*
PRM emph 8.34 (10.35) 10.44 (12.71) 0.07 11.6 (12.64) 8.2 (11.12) <0.0001*
Total exacerbations within 12 months at baseline
(mean, SD)
0.49 (0.98) 0.60 (1.06) 0.01* 0.57 (1.02) 0.54 (1.04) 0.53
Figure 2 Distribution of flow (FEV1) and volume (FVC) BDR in COPD based on (A) spirometric GOLD grades, (B) GOLD groups defined by symptoms, exacerbations, and
spirometric grades (revision 2011), (C) GOLD groups defined by symptoms and exacerbations only (revision 2019), and (D) percentage emphysema <−950 HU.
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subjects with COPD into four GOLD groups (A through D),
defined by either combining spirometric grades with exacer-
bation frequency and symptoms (GOLD revision 2011),
(Figure 2B) or by only exacerbation frequency and symp-
toms without spirometry (GOLD revision 2019) (Figure 2C).
In both classification systems, advanced disease (Group D)
was characterized by a greater prevalence of BDRFVC
(50.8% and 41.4%, respectively) than BDRFEV1 (33.9%
and 28.7%, respectively).
To assess the relationship of BDR to radiographic emphy-
sema (CT density ≤−950 HU), we divided COPD subjects
into quartiles by quantity of emphysema observed on HRCT
(Figure 2D). Subject age did not differ significantly across
the quartiles. BDRFVC was more prevalent in those with
more emphysema (Quartile 4, 49.8 versus 33.7%), in contrast
to those with less emphysema (Quartiles 1 and 2) where
BDRFEV1 was more prevalent.
Volume Responsiveness Correlates with
PRM Analysis of Small Airway Disease
and Emphysema
To evaluate whether BD responders have more small airway
disease in comparison to BD nonresponders, we analyzed
parametric response mapping (PRM) in relationship to FVC
and FEV1 BDR status. PRM analysis demonstrated signifi-
cantly more functional small airway disease (PRMfSAD)
which is equivalent to air trapping in FVC-BD responders
compared with FVC-BD nonresponders, but showed no dif-
ference between FEV1-BD responders and nonresponders
(Figure 3).
Clinical relevance of BDRFVC
FVC-BD responders had lower post-BD FEV1, more emphy-
sema, more small airway disease, and poorer health-related
quality of life measured by SGRQ compared to nonrespon-
ders. FVC-BD responders also had more self-reported use of
inhaled bronchodilators and inhaled steroids relative to FVC-
BD nonresponders. By contrast, FEV1 BD-responders were
associated with current smoking status and fewer exacerba-
tions reported at baseline (Table 2).
Over the 3-year study period, FVC-BD responders had
reduced survival in comparison to FVC-BD nonresponders
(88.1% vs 91.7%, P<0.05) (Figure 4). This difference was
significant in a univariable Cox proportional hazards model
(HR=1.46, CI: 1.02–2.08). In an univariable negative bino-
mial model, BDRFVC was associated with an increased inci-
dence rate ratio (RR) for exacerbations, relative to FVC-BD
nonresponders (RR=1.30, CI:1.12–1.52). However, in multi-
variate models adjusted for known risk factors, including
post-BD FEV1, these associations were no longer significant
for either exacerbation (RR=1.12, CI: 0.96–1.31) or mortal-
ity (HR=1.03, CI=0.71–1.47), Supplemental Table 2.
Finally, to understand the diverging proportions of flow-
based versus volume-based BDR in advanced COPD, we
analyzed subjects who demonstrated BDRFVC but not
BDRFEV1. These subjects represented 32% of all FVC-BD
responders (N=238), and in comparison to individuals who
demonstrated both BDRFEV1 and BDRFVC (N=496), they had
more emphysema (Figure 5A) and more exacerbations during
the follow-up period (Figure 5B). A higher risk of exacerba-
tions was observed in isolated BDRFVC relative to other
COPD subjects who were not isolated FVC-BD responders
(HR 1.71, CI: 1.09–2.67) (Supplemental Table 3). Isolated
BDRFVC was characterized by a higher 3-year mortality rela-
tive to other COPD participants. Nevertheless, stratified by
post-BD FEV1 in a multivariate model, there was no associa-
tion between isolated BDRFVC and exacerbations or mortality
risk (Supplemental Figure 1).
Discussion
In a longitudinal analysis of 2,974 individuals with and
without COPD, we evaluated the prevalence and clinical
Figure 3 Parametric Response Mapping analysis. The extent of small airway disease
(PRMfSAD) shows that FVC-BD responders have more PRMfSAD on functional
imaging in comparison to FVC-BD nonresponders. There is no difference between
FEV1 BD responders and nonresponders in the extent pf PRM
fsad.
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implications of BDR. Focused on distinctions between
BDRFEV1 and BDRFVC, our study revealed several inter-
esting observations.
As reported previously,4,6,11,20 BDR is present in a
majority of participants with COPD. Despite being a com-
mon feature of this disease, it is still often misinterpreted as
a hallmark of asthma, a misconception originating in part by
COPD being defined by “persistent airflow limitation”.12
Reversibility of airflow obstruction or, normalization of
FEV1/FVC ratio after BD administration, is absent in
COPD, but BDR, a measure of BD-induced change in
lung volumes rather than ratios, is frequent and does not
necessarily imply the coexistence of asthma.21 While the
self-reported history of asthma in our cohort was associated
with BDR, this parameter cannot be used to differentiate
between or define asthma or COPD, since it is frequently
observed in both conditions.22 Analyzing BDR among
healthy never-smokers without an asthma history showed
that a significant proportion of these individuals showed
either flow-based or volume-based BDR with frequencies
similar to reported values,23 indicating that BDR also
poorly discriminates diseased from healthy airways.24 Our
data add to the evidence of the lack of association of BDR
with blood eosinophils,25 and we show that average blood
eosinophil counts (BEC) were similar among BD respon-
ders and BD nonresponders, with both FEV1 and FVC-BD
responders having similar BEC compared to FEV1 and FVC
nonresponders, respectively.
Despite such limitations, the clinical significance of
BDR increases when its pattern is analyzed with regard to
changes in both FEV1 and FVC. This is particularly impor-
tant in advanced COPD, where distal airway remodeling
and emphysema with loss of alveolar attachments may lead
to an early expiratory collapse of small airways with sub-
sequent air trapping and dynamic hyperinflation,26,27 result-
ing in a less significant impact on the post-bronchodilator
change in FEV1 in comparison to the change in FVC. The
increase in the prevalence of BDRFVC closely reflected the
progression of emphysema and small airway disease, as
demonstrated in the present study by quantitative HRCT
and PRM. Small airway disease, one of the key features of
COPD, may lead to air-trapping and hyperinflation with an
increase in functional residual capacity (FRC) and a corre-
sponding decrease in IC. BD administration can induce
Figure 4 Kaplan–Meier plot of overall survival up to 3 years: FVC-BD responders (88.1%) vs FVC-BD nonresponders (91.7%) (P<0.05).
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significant reductions in lung hyperinflation, manifested by
a response in FVC or IC even in the absence of significant
improvement in FEV1 in a majority of individuals with
advanced emphysema, and the benefit may be greatest in
those with the most severe disease. These findings suggest
that BDRFVC offers an insight into pathophysiologic pro-
cesses in advanced airway disease, which have been pre-
viously described.10,11
The distribution pattern of BDRFVC was, in agreement
with that reported previously,10,28 infrequent in healthy
subjects and ever-smokers without COPD. In early COPD,
BDRFVC was uncommon relative to BDRFEV1, but became
more prevalent as the disease progressed, being highest in
the most advanced disease, whether defined spirometrically
or by the GOLD grading system.12 In contrast, BDRFEV1
was rare in subjects with spirometrically very severe
COPD, thus failing to identify the actual prevalence of
BD responsiveness in these individuals. This observation
can also explain why FVC-BD responsiveness in the
absence of BDRFEV1 is associated with a higher risk of
exacerbations in univariate analysis while this effect is
lost in a model adjusted for FEV1.
Does BDRFVC have other relevant clinical implications
in COPD management? We found that FVC-BD respon-
ders with COPD had lower post-BD FEV1% predicted,
more often used steroids and inhaled BD, and had more
respiratory symptoms than FVC-BD nonresponders,
despite similar age, sex, smoking history and BMI, all
results suggesting more advanced or active disease.
Although our FVC-BD responsive participants reported
the same frequency of exacerbations in the year before
enrollment as nonresponders, they were more likely to
exacerbate during the 3-year follow-up period and their
mortality was significantly worse than FVC-BD nonre-
sponders. However, these findings were no longer signifi-
cant in a multivariate model adjusted for post-BD FEV1%
predicted. Similar findings were reported in a study where
BDR was tested using salbutamol only,9 in which BDR
identified frequent exacerbators, with the lack of statistical
significance after the inclusion of pre-BD FEV1 as a cov-
ariate. In a different COPD cohort,29 baseline BDR was
predictive of a greater mean rate of FEV1 decline over
3 years than observed in the entire cohort (33 mL/year vs
17 mL/year); however, the mean baseline FEV1 was sub-
stantially higher among BD responders compared to BD
nonresponders. In small randomized controlled trials, BDR
correlated with lower exercise capacity and worse quality-
of-life scores.30
While this study is in agreement with other studies that
failed to demonstrate that BDR represents a distinct clin-
ical phenotype predictive of outcomes,4,8,9 our findings
suggest that, in appropriate clinical settings, analyzing
BDRFVC and BDRFEV1 status may offer treating physi-
cians additional insights about their patients, particularly
with regard to the presence of hyperinflation.
Our study has several limitations. We did not analyze
the actual values of post-BD changes in FEV1 or FVC, but
instead followed the accepted practice of a categorical
classification of BD responsiveness versus and BD
nonresponsiveness.3 We applied one among several exist-
ing criteria proposed to define BDR4 and thus cannot
extend our findings to universal clinical settings or other
definitions. Since the current diagnosis of asthma
Figure 5 Comparison of isolated BDRFVC among individuals with COPD in com-
parison to dual FVC and FEV1 BDR, isolated BDRFEV1 without BDRFVC and com-
plete nonresponsiveness by either FEV1 or FVC: (A) FVC-BD responders who do
not show BDRFEV1 have more emphysema in comparison to the other three groups,
(B) FVC-BD responders who do not show BDRFEV1 have a higher median rate of
exacerbations in comparison to the other groups.
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represented one of the exclusion criteria for the enrollment
in the study, the possible presence of asthma–COPD over-
lap syndrome cannot be precisely analyzed in this report.31
We have also analyzed only currently available data for
subjects who continue to be followed through the
SPIROMICS study cohort, so that the reported associa-
tions with outcomes cannot be considered final. These
limitations are balanced by our goal to relate a common
use of spirometry to clinical management.
Several strengths merit emphasis. One is our large
cohort of ever-smokers without and with COPD, whose
clinical characteristics were well described at baseline and
longitudinally, allowing for the adequate association of
BDR with multiple clinical outcomes. We analyzed several
metrics that reflect BDR, including comprehensive ima-
ging assessment and novel biometric measures such as
PRM, which offered additional insight into pathophysio-
logic processes in COPD. Unlike other studies evaluating
BDR in COPD,9 we attempted optimal BDR testing, via
higher doses of both a short-acting beta-agonist and a
short-acting muscarinic antagonist, and allowed sufficient
time for the nearly full medication effect. Using different
classes of short-acting inhaled agents at twice their usual
recommended dose is supported by established evidence
of their additive effect.32
Conclusion
BDR was highly prevalent among COPD subjects in the
SPIROMICS cohort. Defined using standard criteria,
BDRFEV1 was observed more often in subpopulations of
healthy subjects and ever-smokers either without airflow
obstruction or with early stages of COPD. In contrast,
BDRFVC was more prevalent in advanced COPD and
associated with increases in emphysema and small airway
disease measured by HRCT. BDRFVC status correlated
with increased exacerbations and mortality, although this
association may partly be a consequence of the markedly
reduced FEV1 in individuals with advanced COPD.
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